NCT04689191Unknown3 期
A Randomized, Double-Blind, Controlled, Non-inferiority Phase III Trial of a Group A and C Meningococcal Polysaccharide Vaccine in Healthy Children Aged 2-6 Years
Wei Cun1 个研究点 分布在 1 个国家目标入组 1,280 人开始时间: 2020年9月15日最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 1,280
- 试验地点
- 1
- 主要终点
- Seroconversion rate of Group A meningococcal bactericidal antibody
研究概览
简要总结
This study is a randomized, double-blinded, and controlled phase III clinical trial of the Group A and C meningococcal polysaccharide vaccine to evaluate the safety and immunogenicity of the vaccine in healthy infants aged 2-6 years.
详细描述
This study was divided into two stages. The first stage study was an early safety assessment study among 80 subjects. The first stage study was conducted gradually in 20 subjects aged 18-50 years, 20 subjects aged 7-17 years, and 40 subjects aged 2-6 years. The second phase was a randomized, double-blind, controlled, non-inferiority phase III clinical trial in 1200 healthy infants aged 2-6 years, to evaluate the immunogenicity and safety of the experimantal vaccine after immunization.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 2 Years 至 50 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The First stage study (An early safety assessment study):
- •18-50 years group:
- •Inclusion Criteria:
- •Healthy adults aged 18 to 50 years.
- •Proven legal identity.
- •Participants should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
- •Participants should be able to communicate well with investigators, understand and comply with the requirements of this trial.
- •Axillary temperature ≤37.0℃.
排除标准
- •Contraindications for vaccination.
- •History of allergy to vaccines or drugs.
- •History of Epidemic Cerebrospinal Meningitis.
- •Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
- •Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine within 3 years.
- •Immunization with any vaccine within 30 days.
- •Patients with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
- •History of abnormal clinical manifestations and serious diseases to be excluded, including but not limited to nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism, bones and other system diseases, and a history of malignant tumors.
- •Those who developed acute disease or acute attack of chronic disease.
- •Surgical removal of spleen or other important organs for any reason.
- •History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
- •Blood products such as immunoglobulin were received within 30 days before vaccination.
- •Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
- •Those who participated in other clinical studies.
- •Participants who have a positive pregnancy test, or are breastfeeding, or plan to become pregnant, or plan to donate sperm or eggs from the screening to 12 months after the second vaccination.
- •Any other situations judged by investigators as not suitable for participating in this study.
- •7-17 years group:
- •Inclusion Criteria
- •Healthy volunteer aged 7 to 17 years.
- •Proven legal identity.
- •Participants and their legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
- •Participants and their legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
- •Axillary temperature ≤37.0℃.
- •Exclusion Criteria:
- •Contraindications for vaccination.
- •History of allergy to vaccines or drugs.
- •History of Epidemic Cerebrospinal Meningitis.
- •Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
- •Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 3 years.
- •Immunization with any vaccine within 30 days.
- •Patients with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
- •Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
- •Those who developed acute disease or acute attack of chronic disease.
- •Surgical removal of spleen or other important organs for any reason.
- •History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
- •Blood products such as immunoglobulin were received within 30 days before vaccination.
- •Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
- •Those who participated in other clinical studies.
- •Women with positive pregnancy test after menarche.
- •Any other situations judged by investigators as not suitable for participating in this study.
- •2-6 years group:
- •Inclusion Criteria
- •Healthy children aged 2 to 6 years.
- •Proven legal identity.
- •Participants' legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
- •Participants' legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
- •Axillary temperature ≤37.0℃.
- •Exclusion Criteria:
- •Contraindications for vaccination.
- •History of allergy to vaccines or drugs.
- 另有 36 项未显示
研究组 & 干预措施
Experimental Vaccine
Experimental
One dose of Experimental Group A and C meningococcal polysaccharide vaccine
干预措施: Experimental Group A and C meningococcal polysaccharide vaccine (Biological)
Active Comparator Vaccine
Active Comparator
One dose of Control Group A and C meningococcal polysaccharide vaccine
干预措施: Control Group A and C meningococcal polysaccharide vaccine (Biological)
结局指标
主要结局
Seroconversion rate of Group A meningococcal bactericidal antibody
时间窗: 28 days after vaccination
Seroconversion rate of Group A meningococcal bactericidal antibody at day 28 after vaccination
Seroconversion rate of Group C meningococcal bactericidal antibody
时间窗: 28 days after vaccination
Seroconversion rate of Group C meningococcal bactericidal antibody at day 28 after vaccination
次要结局
- Adverse reactions/events rate(28 days after vaccination)
- Serious adverse events(6 months after the second vaccination)
- GMT of Group A meningococcal bactericidal antibody(28 days after the second vaccination)
- GMT of Group C meningococcal bactericidal antibody(28 days after the second vaccination)
- Adverse reactions/events rate(7 days after vaccination)
研究者
Wei Cun
Professor
Chinese Academy of Medical Sciences
研究点 (1)
Loading locations...
相似试验
Unknown
3 期
A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide VaccineMeningitis, MeningococcalNCT04689165Wei Cun1,280
Unknown
3 期
Yiqi Wenjing Prescriptions Preventive Efficacy of Oxaliplatin-induced Peripheral Neuropathy Clinical TrialChemotherapy-induced Peripheral NeuropathyColorectal CancerNCT04690283Nanjing NingQi Medicine Science and Technology Co., Ltd.360
招募中
3 期
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)Chronic Myelomonocytic LeukemiaNCT06647862ImmuneOnco Biopharmaceuticals (Shanghai) Inc.170
Enrolling By Invitation
不适用
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT06048926The First Affiliated Hospital with Nanjing Medical University30
进行中（未招募）
1 期
A study investigating copanlisib in combination with standard treatment versus standard treatment alone in order to see if copanlisib improves the response to standard treatment in patients with relapsed indolent non-Hodgkin's lymphoma.Patients with relapsed indolent non-Hodgkin's lymphomaMedDRA version: 20.0Level: PTClassification code 10029600Term: Non-Hodgkin's lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001088-38-CZBayer AG520